See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The U.S. Food and Drug Administration (FDA) has approved a new drug for ...
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioid analgesic designed to treat moderate to ...
The Modesto Bee on MSN
Opioid prescriptions in Stanislaus County are the highest in CA. What the numbers show
More than 253,200 prescriptions were written in this county in 2025, for a rate of 434 per 1,000 residents, almost twice the statewide rate.
With the goal of informing clinician practice, a new study explores the harms and benefits of continuing and of discontinuing the long-term prescription of opioid medicines to adults with chronic pain ...
For some people, simply putting on pants can be excruciatingly painful. New policy will put pain relief out of reach for many ...
By Siddhi Mahatole Oct 8 (Reuters) - Drugmaker Viatris said on Thursday it would buy Pacira BioSciences for $1.65 billion in cash, adding two non-opioid pain treatments to its portfolio as it looks to ...
Welltica+ on MSN
Nearly eight years on daily opioids didn’t ease chronic back pain, and something else got worse
A head-to-head comparison with similar patients who never took the drugs lands in an unexpected place for people managing ...
Prescriptions Rising for a New Non-Opioid Analgesic, but Clinicians Are Still Learning Where It Fits
Prescriptions for the new non-opioid pain medication suzetrigine more than doubled between April and August 2025, according to analysis from Epic Research. The increase indicates a growing interest in ...
Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is "a pretty big deal." "This is a pretty big deal," Gupta said. "As you just mentioned, it's been since 1998 that ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill received ...
(The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results